```
16/30 - (C) Derwent
        90-181364 [24]
        C90-078781
        N90-140904
        ***Vascular*** ***endothelial*** cell growth factor - is obtd. by
      condensing serum-free cultured supernatant soln. of human diploid
      fibroblast cells and purifying
DC -
        BO4 D16 P34
        (TORA ) TORAY IND INC
        (AJIN ) AJINOMOTO KK
NP
        J02117698 A 900502 DW9024
PN
       88JP-271389 881027
AP
        88JP-271389 881027
        A61K-037/24 A61K-049/00 A61L-027/00 C07K-015/12 C12P-021/02
     C12R-001/91
        J02117698 Purified ***vascular*** ***endothelial*** cell growth
      factor is obtd. by condensing serum-free cultured supernatant soln. of
     human diploid fibroblast cells via ultrafiltration and purifying
     condensed soln. via heparin cephallose affinity chromatography and
     reverse phase HPLC. Factors show growth promoting activity to
     ***vascular*** ***endothelial*** cells and show no activity to
      Balb/3T3 and human diploid fibroblast-cells. Factors do not inhibit
     combining of 125I-FGF to HepG2 cell surface FGF receptors.
       USE/ADVANTAGE - Endothelial cell growth factor (ECGF) are useful for
     treatments for burn and cardiovascular disorders. Also, ECGF are
     useful material for treatments and diagnosis of malignant tumour,
     retinitis, chronic rheumatism, etc.. Also ECGF are hingly purified and
     obtd. by method of higher productivity and stability over conventional
     methods. (4pp Dwg.No.0/0)
```

```
22/30 - (C) Derwent
       89-088700 [12]
       C89-039214
        ***Vascular*** ***endothelial*** cell growth factor protein - used
      for treatment of e.g. wound and cardio angiopathy and for diagnosing
      e.g. tumours, etc.
DC
       B04 D16
PA
        (TORA ) TORAY IND INC
NP
PN
        J01038100 A 890208 DW8912
       87JP-193303 870731
       87JP-193303 870731
       A61K-037/02 C07K-015/06 C12P-021/00 C12R-001/91
       J01038100 ***Vascular*** ***endothelial*** cell growth factor
      (ECGF) protein has a M.W. under the non-redn condition of 38000-48000.
      ECGF is inactivated by reducing treatment. The isoelectric point is
     8.5-9.0.
       USE/ADVANTAGE - ECGF is useful for treatment of e.g. wound and
     cardio-angiopathy, and for diagnosis of e.g. tumours, retinopathy,
     chronic rheumatism. ECGF can be efficiently and safely obtd.
       In an example, human diploid fibroblast is grown in Eagle MEM medium
      including 5% bovine serum, and grown in a medium including no serum.
     The obtd supernatant soln is concn, and ECGF active ingredients are
      absorbed in a column, eluated and absorbed TSK gel Ether-5PW in the
```

presence of ammonium acetate. The obtd fraction is eluted and

Dwg. No. 0/3)

subjected to SDS-PAGE (contg no reducing agent) to obtain M.W. of 3S000-48000. When a reducing agent is present, ECGF activity is not detected. By PAGE isoelectric method, pI can be obtd 8.5-9.0. (4pp